Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Head Neck. 2022 Dec;44(12):2686-2695. doi: 10.1002/hed.27178. Epub 2022 Sep 2.
Chondrosarcomas of the sinonasal cavity and skull base are uncommon malignancies. We sought to provide long-term outcomes at two tertiary care centers.
Patients with chondrosarcoma treated between 2000 and 2021 were included. The primary outcomes were overall survival (OS) and disease-specific survival (DSS).
Thirty-eight patients met inclusion criteria. Fourteen patients had sinonasal (36.8%), 7 petroclival (18.4%), and 17 other primary skull base lesions (44.7%). Twenty-eight patients (73.7%) underwent radiation with an average dose of 67.3 ± 15.1 Gy. Eighteen patients (47.4%) required revision surgery for recurrence. 1, 5, and 10-year OS were 97.3%, 93.1%, and 74.7%. DSS at 5- and 10-year survival was 95.7%. Adjuvant radiation was associated with improved OS (HR: 0.12; 95% CI: 0.02-0.75, p = 0.023).
We present our experience over the last 20 years treating chondrosarcomas. Favorable survival outcomes can be achieved but recurrence requiring repeat resection is common.
发生于鼻腔鼻窦和颅底的软骨肉瘤是一种罕见的恶性肿瘤。我们旨在通过两家三级医疗机构来提供此类疾病的长期预后信息。
纳入了 2000 年至 2021 年间接受治疗的软骨肉瘤患者。主要结局为总生存率（OS）和疾病特异性生存率（DSS）。
38 名患者符合纳入标准。14 名患者为鼻腔鼻窦来源（36.8%），7 名患者为岩斜区来源（18.4%），17 名患者为其他颅底来源病变（44.7%）。28 名患者（73.7%）接受了放疗，平均剂量为 67.3±15.1Gy。18 名患者（47.4%）因复发而需要再次手术。1、5、10 年 OS 分别为 97.3%、93.1%和 74.7%。5 年和 10 年 DSS 分别为 95.7%。辅助放疗与 OS 改善相关（HR：0.12；95%CI：0.02-0.75，p=0.023）。
我们介绍了过去 20 年治疗软骨肉瘤的经验。虽然可以获得良好的生存结果，但复发需要再次切除的情况很常见。
